Five Steps to Ensure Accurate 340B Program Data
Hospitals and health systems proactively monitor and manage data accuracy with third-party administrators to maintain 340B program compliance and maximize…
FDA Approves Datopotamab for Treatment of EGFR-Mutated Non-Small Cell Lung Cancer
Datopotamab deruxtecan gains FDA approval, offering new hope for adults with advanced EGFR-mutated non-small cell lung cancer after prior therapies.
ADA 2025: Advancing CGM Adoption for Type 2 Diabetes Care
Continuous glucose monitoring (CGM) is poised to transform type 2 diabetes management.
IVIG-Glucocorticoid Combination Therapy Reduces Need for Adjunctive Immunotherapy in Pediatric MIS-C
Glucocorticoids alone were found to reduce treatment failure and fever duration, but the combination with intravenous immunoglobulin (IVIG) significantly reduced…
ADA 2025: Ready-to-Use Glucagon Empowers Diabetes Patient Safety
Ready-to-use glucagon simplifies hypoglycemia rescue by providing easy-to-use options for patients and caregivers.
Understanding Recent Changes to 505(b)(2) Drugs and Reimbursement
These changes are creating operational challenges for oncology infusion centers.
Psychedelic Group Therapy Expands From Cancer Care to Treat PTSD in Active Duty Military
Manish Agrawal, MD, discusses the expanding influence of his group-based psychedelic therapy model in oncology and beyond, highlighting its adaptation…
Transitions of Care Pharmacists Mitigate Readmission Rates for COPD
Pharmacists have the skills to improve patient outcomes and relieve burdens on other providers.
Lorundrostat Shows Clinically Meaningful Outcomes in Patients With CKD and Hypertension
Lorundrostat reduces blood pressure and urine albumin-to-creatinine ratio in patients with chronic kidney disease (CKD) and hypertension.
Vizient Announces Arun Ramasubramanian as President, Data and Digital
IRVING, Texas–(BUSINESS WIRE)–Vizient today announced that Arun Ramasubramanian has joined the company as president of its Data and Digital business…